Reflecting on Advances in NSCLC Treatment Over the Past 10 Years

Kammi Fox-Kay, Cathy Simmons, and Lauren Welch describe their perspectives on advances in NSCLC treatment over the past decade, focusing on the development of targeted agents and the discovery of new molecular targets for therapy, as well as the expanding use of immunotherapy as first-line therapy for NSCLC. They describe this as a “thrilling time” in NSCLC treatment where they can reassure their patients that they will be able to live longer with their disease, even at stage III or IV.